• H.C. Wainwright upgraded NASDAQ:CORT to "Buy" and increased its price target from $90 to $105.
• The ROSELLA Phase 3 trial showed a 35% reduction in the risk of death for patients receiving the combination therapy of relacorilant and nab-paclitaxel.
• Corcept's stock price reflects a 13.74% increase, with a significant surge in trading volume following the trial's success.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company focused on developing medications that modulate the effects of the hormone cortisol to treat severe disorders, including oncologic conditions. Recently, H.C. Wainwright upgraded CORT's stock to "Buy" and increased its price target from $90 to $105. At the time of this announcement, the stock was priced at approximately $41.87.

The upgrade by H.C. Wainwright comes amid significant developments for Corcept. The company's stock has seen a notable increase, with trading volume reaching over 3 million shares. This surge follows the successful results from the ROSELLA Phase 3 trial, which tested the combination of relacorilant and nab-paclitaxel in treating platinum-resistant ovarian cancer. The trial showed a 35% reduction in the risk of death for patients receiving the combination therapy.

The positive trial results have had a substantial impact on CORT's stock performance. The stock is currently priced at $41.30, reflecting a 13.74% increase, with a change of $4.99. Today's trading has seen fluctuations between a low of $40.46 and a high of $52.84. Over the past year, the stock has reached a high of $117.33 and a low of $32.99.

Corcept's market capitalization stands at approximately $4.34 billion, with a trading volume of 5,304,058 shares. The successful achievement of the primary objective in the late-stage clinical trial marks a significant milestone for the company, reinforcing its mission to advance cancer treatment options. The combination therapy was well-tolerated, with adverse events similar to those experienced with nab-paclitaxel monotherapy.